Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development
- Written by PR Newswire
![]() |
PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical characterization step in the candidate development process to ensure drug efficacy and...















